SMD Rise PCLBKK:SMD100-R 60 Debt-to-Equity is 0.49 as of Mar. 2026, which is 69% above its 10-year median of 0.29. GuruFocus rates BKK:SMD100-R with a GF Score™ of 60/100 and a GF Value™ of ฿24.10. The stock has 6 warning signs investors should review. Among 97 Medical Distribution companies, SMD Rise PCL ranks worse than 51.55% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for SMD Rise PCL's Debt-to-Equity or its related term are showing as below:
BKK:SMD100-R'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.29 Max: 1.32
Current: 0.49
During the past 8 years, the highest Debt-to-Equity Ratio of SMD Rise PCL was 1.32. The lowest was 0.05. And the median was 0.29.
BKK:SMD100-R's Debt-to-Equity is ranked worse than 51.55% of 97
companies
in the Medical Distribution industry
Industry Median: 0.48
vs BKK:SMD100-R: 0.49
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
SMD Rise PCL Debt-to-Equity Related Terms
SMD Rise PCL Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for SMD Rise PCL's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:SMD100-R vs MCK, CAH, COR: Debt-to-Equity Comparison
For the Medical Distribution subindustry, SMD Rise PCL's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMD Rise PCL Debt-to-Equity vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, SMD Rise PCL's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where SMD Rise PCL's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMD Rise PCL (BKK:SMD100-R) has a Debt-to-Equity of 0.49 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SMD Rise PCL and its competitors. This is 69% above median its historical median of 0.29. Over the past decade, SMD Rise PCL's Debt-to-Equity has ranged from 0.05 to 1.32. According to the industry distribution chart, SMD Rise PCL ranks #50 out of 97 companies in the Medical Distribution industry, placing it in the top 51.5%.
Is SMD Rise PCL's Debt-to-Equity too high?
SMD Rise PCL's current Debt-to-Equity of 0.49 is 69% above median its 10-year median of 0.29. Over the past 10 years, this metric has ranged from a low of 0.05 to a high of 1.32. The Medical Distribution industry median Debt-to-Equity is 0.48. SMD Rise PCL's value of 0.49 is 2.1% above this industry median. Based on the distribution chart, SMD Rise PCL ranks #50 out of 97 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, SMD Rise PCL has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does SMD Rise PCL's Debt-to-Equity compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, SMD Rise PCL ranks #50 out of 97 companies for Debt-to-Equity. This places SMD Rise PCL in the lower half of its industry. The industry median Debt-to-Equity is 0.48. SMD Rise PCL's value of 0.49 is 2.1% above this benchmark. Historically, SMD Rise PCL's own Debt-to-Equity has ranged from 0.05 to 1.32 over the past decade. While the company's 10-year median is 0.29 vs. the industry median of 0.48, SMD Rise PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Distribution company?
The median Debt-to-Equity among Medical Distribution companies is 0.48, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SMD Rise PCL's current Debt-to-Equity of 0.49 is 2.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on SMD Rise PCL and its competitors. For the Medical Distribution industry, the median Debt-to-Equity is 0.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMD Rise PCL's current Debt-to-Equity is 0.49, which is 69% above median its own 10-year median of 0.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMD Rise PCL stock overvalued right now?
SMD Rise PCL (BKK:SMD100-R) has a current Debt-to-Equity of 0.49. The stock's GF Value™ is ฿24.10, compared to a current price of ฿5.85 — trading 75.7% below its estimated fair value. The current Debt-to-Equity is 0.49, which is 69% above median its 10-year median of 0.29 and 2.1% above the Medical Distribution industry median of 0.48. SMD Rise PCL's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For SMD Rise PCL (BKK:SMD100-R), the current Debt-to-Equity is 0.49 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMD Rise PCL (BKK:SMD100-R) Overvalued in 2026?
Based on GuruFocus' analysis, SMD Rise PCL stock appears to be undervalued.
The current stock price of ฿5.85 is trading 75.7% below its estimated GF Value™ of ฿24.10.
Key valuation signals for BKK:SMD100-R:
Debt-to-Equity: 0.49 (69% above median its 10-year median of 0.29)
GF Value™: ฿24.10 vs. price of ฿5.85 (75.7% below fair value)
Industry Position: 2.1% above the Medical Distribution median (#50 of 97)
No single metric tells the full story. See the BKK:SMD100-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address222,222/1-2 Moo 1, Rattanathibet Road, West Inn Complex Building, 10th Floor, Bang Rak Yai Subdistrict, Bang Bua Thong District, Nonthaburi Province, Bangkok, THA, 11110
SMD Rise PCL, formerly Saintmed PCL is engaged in the import and distribution of medical devices and equipment, rental services for medical equipment, and providing services related to medical equipment. It operates in Thailand. The Group is engaged in three operating segments: Sale of medical devices and equipment, medical supplies, Services of medical equipment at sleep lab centers and repair services, and Revenue from rental of medical equipment at wellness centers and other services. The Group is managed and operates principally in Thailand.
60GF Score
Get the complete analysis for BKK:SMD100-R
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SMD100-R has been successfully added to your 
